Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging
Part of paid clinical trials in Dallas, Texas.
- Sponsor
- Urology Clinics of North Texas
- Study ID
- NCT07069465
- Phase
- EARLY_PHASE1
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- flotufolastat F 18 — DIAGNOSTIC_TESTPSMA-PET scan with Posluma agent (x2)
- Relugolix 120 MG — DRUGAdministration of oral ADT for 3 and 6 weeks
- Serum PSA and Testosterone — DIAGNOSTIC_TESTSerum PSA and testosterone at study initiation and again at 3 and 6 weeks after initiation of ADT
Study Details
This is a pilot, non-randomized, two-cohort interventional study in patients who meet the inclusion criteria, using an FDA- approved androgen deprivation agent for a 3 or 6-week course of treatment prior to standard-of-care RALP with PLND. The intent of the study is to determine the effect of ADT on PSMA expression as measured by PSMA-PET scan. A second PSMA-PET scan will be performed after ADT for either 3 or 6 weeks, depending on cohort, prior to RALP and PLND.
Key Dates
- Start date
- Jun 15, 2024
- Status verified
- Jun 2025
- Primary completion
- Nov 6, 2024
- Completion
- Nov 6, 2024
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- DIAGNOSTIC
Arms
- Active Comparator: Cohort A5 patients (Cohort A) undergo a second study PSMA-PET with POSLUMA® 3 weeks after initiation of ADT and discontinue ADT immediately after the scan is completed.
- Active Comparator: Cohort B5 patients (Cohort B) undergo a second study PSMA-PET with POSLUMA® 6 weeks after initiation of ADT and discontinue ADT immediately after the scan is completed.
Primary Outcome Measure
1. Mean change in maximum standardized uptake value (SUVmax) per lesion as measured by PSMA-PET (POSLUMA®) from baseline to post-ADT [ Time Frame: 3-6 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Urology Clinics of North Texas | Dallas | Texas | 75231 | - |
Find similar trials in Dallas, TX
By condition
By specialty
By research site
Related Studies
- Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical ProstatectomyPHASE3 · Recruiting · yair lotan · Dallas, Texas
- A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyPHASE2 · Recruiting · Astellas Pharma Global Development, Inc. · Anchorage, Alaska
- International Registry for Men With Advanced Prostate Cancer (IRONMAN)Recruiting · Prostate Cancer Clinical Trials Consortium · Birmingham, Alabama
- Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active SurveillancePHASE3 · Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas